Shalini Andersson, PhD



I have more than 20 years of research experience in the Pharmaceutical industry mainly from discovery and development of small molecules therapeutics and during the last 5 years also from RNA based therapeutics. I have broad experience of management of departments and teams as well as setting and delivering business strategies. I am also involved in several collaborations with biotech companies as well as with academic groups around the globe.

I obtained a PhD in organic and analytical chemistry in 1989 from Linköping University. After a post-doc in Germany, I joined Linköping University as a Senior lecturer in Organic Analytical Chemistry and became an Associate Professor (Docent) in 1996 during which time I also gave birth to 2 children. In 1997, I joined AstraZeneca as a senior researcher and during my career I have held numerous management roles including Senior Director Drug Metabolism and Pharmacokinetics, Head of Enabling Technologies and Head of Lead Optimization, Medicinal Chemistry. I am currently a Head of New Therapeutic Modalities, Cardiovascular, Renal and Metabolic Innovative Medicines unit (CVRM IMED) in AstraZeneca. I have strong experience as a project leader for research projects and business change projects locally and globally within AstraZeneca. I am currently leading the CVRM Delivery of new therapeutic modalities and Targeted Drug Delivery platform projects and I am involved in collaborations with Ionis Pharma, Moderna Therapeutics and MMBio (EU funded) within the RNA field. I have over 40 peer reviewed publications, 2 book chapters and 4 patents and have presented my work at conferences throughout my career including chairing sessions at conferences.


  • European Cooperation in Science and
  • Technology network on Delivery of RNA therapy
  • Oligonucleotide Therapeutic Soc.
  • Swedish Chemical Soc.
  • Swedish Academy of Pharmaceutical Sciences
  • American Chemical Soc & AAPS